Healthcare
Live Price
Offline$12.07
+7.05% today
1Y Change
+27.27%
Window
Jun 20, 2025 → Jun 18, 2026
Coverage: 255 bars · Jun 20, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sino Biopharmaceutical Limited (SBHMY) is a Healthcare stock with a market cap of $84.44B and listed on OTC. The stock last traded around $12.06 and up 27.3% across the available one-year price window (Jun 20, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +7.3%, EPS growth of -35.0%, a dividend yield of 1.7%. What stands out right now is revenue +7.3%, EPS -35.0%, free cash flow +45.4% with operating margin 20.6% and ROIC 7.4%. The dividend is present but secondary, with a yield around 1.7%. Valuation is more restrained than many high-expectation growth names at P/E 23.5 and price/sales 3.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SBHMY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SBHMY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SBHMY Max Drawdown
-44.10%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SBHMY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$26.9B
+3.2% YoY
FY Net Income
$14.6B
+474.3% YoY
Free Cash Flow
$3.5B
-0.2% YoY
Revenue Growth
+7.3%
EPS Growth
-35.0%
Gross Margin
82.0%
Net Margin
15.1%
Income statement
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 31.0B | 28.9B | 26.2B | 26.0B | 26.9B |
| Gross Profit | 25.4B | 23.5B | 21.2B | 21.5B | 21.5B |
| Operating Income | 6.6B | 6.1B | 5.8B | 5.6B | 5.1B |
| EBITDA | 7.8B | 6.1B | 7.0B | 6.7B | 19.9B |
| Net Income | 2.3B | 3.5B | 2.3B | 2.5B | 14.6B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 7.4B | 9.6B | 9.5B | 8.7B | 9.6B |
| Total Assets | 76.1B | 65.4B | 63.6B | 64.1B | 60.5B |
| Total Liabilities | 33.3B | 22.6B | 25.4B | 26.1B | 22.8B |
| Shareholder Equity | 30.7B | 32.0B | 30.5B | 29.7B | 30.3B |
| Total Debt | 16.1B | 9.8B | 12.6B | 14.0B | 12.1B |
| Net Debt | 8.7B | 214M | 3.1B | 5.3B | 2.5B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
5.3B
-0.8% YoY
Capital Expenditures
1.9B
+1.8% YoY
Free Cash Flow
3.5B
-0.2% YoY
Key ratios
Gross Margin
82.0%
Operating Margin
20.6%
Net Margin
15.1%
ROE
11.2%
Debt / Equity
0.52x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.